The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Enhertu Filed for HER2 Low or Ultralow Breast Cancer in Japan
Daiichi Sankyo said on October 4 that it has filed its antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in Japan for its earlier use in HER2 low breast cancer and for the new patient pool of HER2 ultralow breast cancer.…
To read the full story
Related Article
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer in Europe
April 7, 2025
- Enhertu Gets EMA Backing for HER2-Low/Ultralow Breast Cancer
March 4, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer
January 29, 2025
- Enhertu Gets Priority Review for HER2 Low or Ultralow Breast Cancer in US
October 2, 2024
- Enhertu Scores in Earlier Line for HER2-Low Breast Cancer, Shows Promise in Ultralow Cases
June 6, 2024
BUSINESS
- Shionogi, Cilcare Ink Research Collab on Novel Hearing Loss Drugs
May 12, 2025
- Canaglu Now Available in Thailand: Mitsubishi Tanabe
May 12, 2025
- Keytruda Tops Japan Drug Sales Ranking for 19th Month: Encise
May 12, 2025
- Japan Ethical Drug Sales Up 5.2% in March: Crecon
May 12, 2025
- Otsuka, Keio Join Hands to Facilitate “Social Implementation” of Psychedelics
May 12, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…